Skip to main content

Growing prevalence of cancer to augment generic oncology sterile injectable market growth

 


Market Overview:

 

Generic oncology sterile injectable are widely used for the treatment of cancers prostate, breast, colorectal, melanoma, lung, and bronchus. They have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different.

 

Competitive Landscape:

Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Key Market Drivers:

Growing prevalence of chronic disease such as breast, prostate, colorectal, melanoma, lung, and bronchus is driving growth of the generic oncology sterile injectable market. According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Increasing partnership and collaboration in the field of generic oncology sterile injectable is again fostering market growth. For instance, in February 2017 – Baxter International Inc. and ScinoPharm Taiwan, Ltd. announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy.

Covid-19 Impact Analysis

Spread of Covid-19 has impacted the supply and demand of generic oncology sterile injectable. This is attributed to the imposed of lockdown and quarantine policies to curb the spread of infection.

Key Takeaways:

1.      The generic oncology sterile injectable market is expected to exhibit a CAGR of 11.5% over the forecast owing to the growing prevalence of cancer.

2.       North America is expected to gain significant growth over the forecast period owing to the growing initiatives by key players to expand production of generic oncology sterile. For instance, in July 2019, Nexus has entered into an agreement with Wisconsin’s village Pleasant Prairie for the development of a sterile injectable manufacturing facility.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Virology Testing Market Detailed In New Research Report 2023

  Virology testing consist of diagnostic methods that help in early detection of the disease such as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other viral associated disease. Virology testing examines for detection of viral antigens, nucleic acids, and antibodies in the given sample in order to confirm the presence of particular viral infection. There are more than 100 viral diseases identified. Virology Testing Market- Market Dynamics Virology testing market is projected to witness significant growth during forecast period with rising prevalence of virus originated diseases such as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections, severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc. across world. Early and fast diagnosis of virus infection is very essential to start treatment course. According to the World Health Organization (WHO), January 2018 factsheet, all types of influenza in combination causes annual...
Post a Comment
Read more

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering ...
Post a Comment
Read more

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....
Post a Comment
Read more